Call Us:  954-929-4814

If the phone line is busy, please call 954-929-4895 or email us

Phosphohexose Isomerase (PHI) is an enzyme that regulates anaerobic metabolism. This enzyme is the so called Autocrine Motility Factor (AMF), and is one of the main cellular causes of malignancy, i.e. cell migration. It is a neurokine type of cytokine.  PHI also plays a most important role in cells becoming cancerous by turning them into sugar users. It is responsible for channeling the cells into low oxygen glycolysis i.e. fermentation.

Because cancer cells favor anaerobic conditions, PHI is an excellent marker. It can be elevated in developing cancers, existing cancers, or in an acute heart, liver, muscle disease, or acute viral infection. Examples of these acute conditions are myocardial infarction, hepatitis, AIDS, and traumatic muscle injury. If an acute condition can be ruled out, cancer may be the cause of the elevated result, and the 10-12 year cancer developmental period's time may be ticking.

Normal results are (15.6 -  31.4 U/L), however, in an established malignancy, a change even within the normal range could be significant. Take notice that this enzyme is the AMF (autocrine motility factor), causing malignant cancer spread. Consequently, cancer can be spread by dislodging one or more cancer cells during surgery or other procedures, and by the PHI enzyme.

It is one of the major causes of the presence of circulating tumor cells (CTC).  The other one is "mechanical" i.e., needle(biopsy) or knife(surgery).

PHI is one of the components of our exclusive  Cancer Profile™©. 

It is an established FDA approved tumor marker, and has been assigned the procedure code number (CPT) 84087.  There are dozens of literature references to this enzyme as such.

PHI - Phosphohexose Isomerase (performed only at our laboratory)

Cancer testing Cancer Profile hcg testing navarro test Emil K. Schandl Dr. E. K. Schandl Longevity Profile cancer tests anti-aging tests Dr. Schandl cancer prevention cancer treatment management cancer therapy follow up cancer detection early detection and prevention prevention oncoblot test AMAS test circulating tumor cells cancer marker test tumor marker test